Abstract:679 Germline mutations of the breast cancer associated gene 1 (BRCA1) have been identified in about 50% of familial breast cancer cases and about 90% of familial breast and ovarian cancers. BRCA1 mutation carriers have a 50 to 80% lifetime risk for developing breast cancer by age 70. Current screening and chemoprevention strategies are suboptimal and consequently some women who are BRCA1 gene carriers elect to prophylactically have their breasts and/or ovaries removed to reduce their risk. Moreover, current chemopreventative drugs often give adverse effects, primarily due to poor specificity of the compounds to mammary tumor tissues. Thus, there is an urgent need to develop safe and effective drugs for the chemoprevention and therapeutic treatment of breast cancer. In the past years, we have created a mouse model carrying a tissue specific disruption of BRCA1 in mammary epithelium. The mutant mice developed mammary tumors at 7-12 months of age. Our analysis revealed that the tumor progression is accompanied by extensive genetic instability and alteration of a number of oncogenes and tumor suppressor genes. Using this animal model and cell lines derived from mammary tumors, we have been studying effects of genistein, green tea, resveratrol, and Poly(ADP-ribose) polymerase (PARP1) inhibitors on BRCA1-associcated tumor formation in order to provide better understand and therapeutic options of BRCA1-assicated breast cancer. Our study indicated that both genistein and resveratrol inhibit growth of tumor cells in culture, in soft agar colony formation and in an allograft nude mouse model. Genistein treated BRCA1 mutant cells were highly polypoid and displayed extensive chromosome abnormalities. Western blot analysis revealed significant increase of CHK2 phosphorylation upon genistein treatment. These observations suggest that genistein induced activation of cell cycle inhibitors may cause cell cycle arrest and cell death, which account for the reduced growth of mutant cells upon the drug treatment. We found that the apoptosis induced by resveratrol in the tumors is accompanied by the activation of NF-kB pathway, and is also partially due to the activation of CHK2 in DNA damage response. Of note, we failed to detect any preventive or therapeutic effects of green tea in both allograft and BRCA1 conditional animals tested. The effectiveness of PARP-1 inhibitors also seemed more specific to BRCA1 mutant embryonic stem cells rather than BRCA1 mutant mammary tumor cells. These data, although promising, remain to be tested in human BRCA1 associated breast cancer cells. Our long-term goal is to decrease cancer risk of BRCA-mutation carriers and find a safe and effective therapeutic method to cure this disease.

Knockout mouse models and mammary tumorigenesis.

Conditional Knockout Mouse Models of Cancer

BRCA1-associated Tumorigenesis: What Have We Learned from Knockout Mice?

Mouse Models of BRCA1 and Their Application to Breast Cancer Research

Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice

Analyses of Tumor-Suppressor Genes in Germline Mouse Models of Cancer

Mouse Models for BRCA1-associated Breast Cancer

Generation and analysis of Brca1 conditional knockout mice.

If you give a mouse a mutation: comparing the therapeutic utility of renowned mouse models of human cancers

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Mouse models of breast cancer in preclinical research

Different Oncogenes and Reproductive Histories Shape the Progression of Distinct Premalignant Clones in Multistage Mouse Breast Cancer Models

Generation and Characterization of P53 Mutant Mice.

Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo

Conditional Loss of PTEN Leads to Precocious Development and Neoplasia in the Mammary Gland.

Chemoprevention and Therapeutic Treatment of Brca1 Associated Breast Cancer in Conditional Knockout Mice

Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice

Canine as a Comparative and Translational Model for Human Mammary Tumor

MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer

Tumor formation inBrca1 conditional mutant mice

Conditional knockout of N-Myc and STAT interactor disrupts normal mammary development and enhances metastatic ability of mammary tumors